<!DOCTYPE html>
<html lang="en">
<head><!-- Google Tag Manager --> <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-N4XZHNC');</script> <!-- End Google Tag Manager -->

<title>Darolutamide: Mechanism, Side Effects, and Dosage</title>
  <meta charset="utf-8">
  
  <link href="urology2.css" rel="stylesheet">

<meta name="keywords" content="Darolutamide, antiandrogen, androgen receptor blocker, Castration Resistant Prostate Cancer" >
<meta name="description" content="Mechanism, side effects and dosage of darolutamide, an androgen recepter blocker for castration resistant prostate cancer, from the online textbook of urology by D. Manski" >
<meta name="author" content="Dr. med. Dirk Manski" >
<meta name="copyright" content="Dirk Manski" >
<meta name="robots" content="index">
<meta name="robots" content="follow">
<meta name="viewport" content="width=device-width, initial-scale=1">
 </head>

<body><!-- Google Tag Manager (noscript) --> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-N4XZHNC" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> 
<header>
    <a class="ribbon" tabindex="-1" title="back to start!" href="https://www.urology-textbook.com/index.html">
	   <p><big>Urology-Textbook.com</big><br>
       <br>
       <small>Up-to-date urology insights from Dirk Manski</small></p>
    </a>  
</header>
<main> 
<article>
<nav role="navigation">
<div id="menuToggle">
<input type="checkbox" id="menuCheckbox" />
     <span></span>
    <span></span>
    <span></span>
<ul id="menu">
<li>
        <a href="https://www.urology-textbook.com/anatomy.html">
          <label for="menuCheckbox" onclick="this.parentNode.click();">Anatomy</label>
        </a>
      </li>
<li><a href="https://www.urology-textbook.com/signs-and-symptoms.html">Signs and Symptoms</a></li>
<li><a href="https://www.urology-textbook.com/examinations.html">Examinations</a></li>
<li><a href="https://www.urology-textbook.com/surgical-management.html">Surgical Management</a></li>
<li><a href="https://www.urology-textbook.com/pharmacology.html">Pharmacology</a></li>
<li><a href="https://www.urology-textbook.com/kidneys.html">Kidneys</a></li>
<li><a href="https://www.urology-textbook.com/ureters.html">Ureters</a></li>
<li><a href="https://www.urology-textbook.com/bladder.html">Bladder</a></li>
<li><a href="https://www.urology-textbook.com/prostate.html">Prostate</a></li>
<li><a href="https://www.urology-textbook.com/urethra.html">Urethra</a></li>
<li><a href="https://www.urology-textbook.com/penis.html">Penis</a></li>
<li><a href="https://www.urology-textbook.com/testes.html">Testes</a></li>
<li><a href="https://www.urology-textbook.com/adrenal-glands.html">Adrenal Glands</a></li>
<li><a href="https://www.urology-textbook.com/common-diseases.html">Common Diseases</a></li>
<li><a href="https://www.urology-textbook.com/urologic-surgery.html">Urologic Surgery</a></li>
<li><a href="https://www.urology-textbook.com/index-urology.html">Index</a></li>
<li><a href="https://www.urology-textbook.com/medical-abbreviations.html">Abbreviations</a></li>
<li><a href="https://www.urology-textbook.com/urology-news.html">News</a></li>
<li><a href="https://www.urology-textbook.com/links.html">Links</a></li>
</ul>

</div>
</nav>

<p id="brotkrumen">&nbsp;You are here: <a href="https://www.urology-textbook.com/index.html">Urology Textbook</a> &gt; <a href="https://www.urology-textbook.com/pharmacology.html">Drugs in Urology</a> &gt; Darolutamide</p>

<h1>Darolutamide: Mechanism, Side Effects, Contraindications, and Dosage</h1>

<h2>Indications for Darolutamide</h2>

    <h3>Castration-sensitive metastatic prostate cancer (M1 CSPC) with high tumor burden:</h3> 
<p>In randomized trials, the triplet combination of standard hormonal therapy intensified with darolutamide and <a href="docetaxel.html">docetaxel chemotherapy</a> showed advantages in terms of survival and disease progression. Triplet therapy in the ARASENS trial led to better survival (HR 0.68) and prolonged progression-free survival compared to hormone therapy and docetaxel (Smith et al., 2022a). Triple therapy with darolutamide has been approved in the USA since 2022 and in Europe since 2023.</p> 

<h3>Castration-resistant non-metastatic prostate cancer (M0 CRPC):</h3> 
<p>Darolutamide is a treatment option for patients with rising PSA levels under androgen deprivation therapy without metastasis in imaging studies (<a href="https://www.urology-textbook.com/renal-scintigraphy.html">scintigraphy</a>, <a href="ct-scan.html">CT-scan</a>). The approval is limited to patients at high risk: PSA doubling time under 10 months. In the pivotal study (ARAMIS), treatment with darolutamide combined with classic antiandrogen therapy improved metastasis-free survival (40 months vs. 18 months with placebo and hormone therapy). Overall survival was improved as a trend (Fizazi et al., 2019).</p>

<p>Darolutamid is <b>not approved</b> for <a href="https://www.urology-textbook.com/prostate-cancer-castration-resistant.html">treatment of castration-resistant metastatic prostate cancer</a> (M1 CRPC).</p>

<h2>Mechanism of Action of Darolutamide</h2> 

<p>Darolutamide inhibits the <a href="male-hormones-testosterone.html">signal transduction of the androgen receptor</a>: </ p>
<ul title="Effects of Darolutamide">
<li>Competitive inhibition of the androgen binding to the androgen receptor </li>
<li>Prevents translocation of activated receptors to the cell nucleus </li>
<li>Inhibits the binding of the activated androgen receptor to the DNA </li>
</ul>

<h2>Pharmacokinetics of Darolutamide</h2>

<p>100% <a href="bioavailability.html">bioavailability</a> independent from meals, 96% plasma protein binding, hepatic metabolism of Darolutamide mainly via CYP2C8 and CYP3A4, half-life 3 days, renal (65%) and fecal excretion of the inactive metabolites. 
</p>

<h2>Side Effects of Darolutamide</h2>

<p>The most common side effects are fatigue (16%). Increased cardiovascular risk (e.g., heart failure 2% vs. 1%). Mild neutropenia or increased liver enzymes. Compared to apalutamide or enzalutamide, there are fewer central nervous system side effects such as falls, epilepsy or fatigue (Halabi et al., 2021).</p>

<h3>Interactions with Darolutamide</h3> 

<p>CYP3A4 inducers such as rifampicin reduce efficacy, caution with CYP3A4 inhibitors such as antifungals.</p>

<h2>Contraindications for Darolutamide</h2> 

<ul>
<li>Allergy and intolerance </li>
<li>Women and children </li>
</ul>

<h2>Dosage of Darolutamide</h2> 

<p>600 mg darolutamide (two 300 mg capsules) p.o. 2-0-2 with the meals, the daily dosage is 1200 mg. The addition of prednisolone is unnecessary. Reduce the dosage to 300 mg 1-0-1 in case of renal or hepatic side effects. Discontinue treatment in patients with progressive disease or persistent intolerance to darolutamide.</p>

<br>
<br><div id="ad-footer">
<!-- ad-footer -->
<ins class="adsbygoogle"
     style="display:inline-block;width:500px;height:250px"
     data-ad-client="ca-pub-9284927104423861"
     data-ad-slot="8746163219"></ins>
 <script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>
</div>
<br><table id="navigation_unten">
<tr>
 
<td><a href="https://www.urology-textbook.com/apalutamide.html">Apalutamide</a></td>
<td><a class="nav4" href="https://www.urology-textbook.com/index-urology.html">Index</a></td>
<td><a class="nav3" href="https://www.urology-textbook.com/cephalosporins.html">Cephalosporins</a></td>
 
</tr>
</table>

<br>
<br>
Index: <a href="https://www.urology-textbook.com/index-urology-a.html">1&ndash;9</a> <a href="https://www.urology-textbook.com/index-urology-a.html">A</a> <a href="https://www.urology-textbook.com/index-urology-b.html">B</a> <a href="https://www.urology-textbook.com/index-urology-c.html">C</a> <a href="https://www.urology-textbook.com/index-urology-d.html">D</a> <a href="https://www.urology-textbook.com/index-urology-e.html">E</a> <a href="https://www.urology-textbook.com/index-urology-f.html">F</a> <a href="https://www.urology-textbook.com/index-urology-g.html">G</a> <a href="https://www.urology-textbook.com/index-urology-h.html">H</a> <a href="https://www.urology-textbook.com/index-urology-i.html">I</a> <a href="https://www.urology-textbook.com/index-urology-j.html">J</a> <a href="https://www.urology-textbook.com/index-urology-k.html">K</a> <a href="https://www.urology-textbook.com/index-urology-l.html">L</a> <a href="https://www.urology-textbook.com/index-urology-m.html">M</a> <a href="https://www.urology-textbook.com/index-urology-n.html">N</a> <a href="https://www.urology-textbook.com/index-urology-o.html">O</a> <a href="https://www.urology-textbook.com/index-urology-p.html">P</a> <a href="https://www.urology-textbook.com/index-urology-q.html">Q</a> <a href="https://www.urology-textbook.com/index-urology-r.html">R</a> <a href="https://www.urology-textbook.com/index-urology-s.html">S</a> <a href="https://www.urology-textbook.com/index-urology-t.html">T</a> <a href="https://www.urology-textbook.com/index-urology-u.html">U</a> <a href="https://www.urology-textbook.com/index-urology-v.html">V</a> <a href="https://www.urology-textbook.com/index-urology-w.html">W</a> <a href="https://www.urology-textbook.com/index-urology-xyz.html">X Y Z</a> 

<br>
<br>
<h3>References</h3>

<p>
K. Fizazi et al., “Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.,” NEJM, vol. 380, no. 13, pp. 1235–1246, 2019.
</p>

<p>S. Halabi et al., “Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.,” J Urol, vol. 206, no. 2, pp. 298–307, 2021, doi: 10.1097/JU.0000000000001767.
 </p>

<p>M. R. Smith et al., “Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.,” NEJM, vol. 386, no. 12, pp. 1132–1142, 2022, doi: 10.1056/NEJMoa2119115.</p>
  

<br>
<br>
<p><img src="https://images0.urology-textbook.com/deutsch.gif">&nbsp; Deutsche Version: <a href="https://www.urologielehrbuch.de/darolutamid.html">Darolutamid</a></p>

<br>
</article>
</main>
<footer class="grid">
    <ul id="footer-nav">
    		<li>Copyright by Dr. med. Dirk Manski </li>
		<li><a href="https://www.urology-textbook.com/privacy-policy.html">Privacy policy</a></li>
		<li><a href="https://www.urology-textbook.com/disclaimer.html">Disclaimer</a></li>
	</ul>
	<a class="steady-login-button" data-size="medium" data-language="en" style="display: none;"></a>
</footer>
</body>
</html>
 
